Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis
Autore:
Richert, ND; Ostuni, JL; Bash, CN; Leist, TP; McFarland, HF; Frank, JA;
Indirizzi:
Ctr Clin, Lab Diagnost Radiol Res, Bethesda, MD USA Ctr Clin Bethesda MD USA Clin, Lab Diagnost Radiol Res, Bethesda, MD USA NINDS, NIH, Neuroimmunol Branch, Bethesda, MD 20892 USA NINDS Bethesda MDUSA 20892 , Neuroimmunol Branch, Bethesda, MD 20892 USA Uniformed Serv Univ Hlth Sci, Dept Radiol, Bethesda, MD 20814 USA Uniformed Serv Univ Hlth Sci Bethesda MD USA 20814 Bethesda, MD 20814 USA Childrens Natl Med Ctr, Dept Diagnost Imaging & Radiol, Washington, DC USAChildrens Natl Med Ctr Washington DC USA ng & Radiol, Washington, DC USA
Titolo Testata:
MULTIPLE SCLEROSIS
fascicolo: 1, volume: 7, anno: 2001,
pagine: 49 - 58
SICI:
1352-4585(200102)7:1<49:IBAIMP>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
SERIAL MAGNETIZATION-TRANSFER; LYSOLECITHIN-INDUCED DEMYELINATION; APPEARING WHITE-MATTER; HIGH-DOSE STEROIDS; MS LESIONS; TRANSFER RATIO; CEREBROSPINAL-FLUID; ENHANCING LESIONS; AXONAL DAMAGE; DOUBLE-BLIND;
Keywords:
multiple sclerosis; intravenous methylprednisolone; MRI; magnetization transfer imaging; interferon beta-1b gadolinium; contrast enhancing lesions;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
59
Recensione:
Indirizzi per estratti:
Indirizzo: Richert, ND NIH, Lab Diagnost Radiol Res, Bldg 10,B1N256, Bethesda, MD 20892 USA NIH Bldg 10,B1N256 Bethesda MD USA 20892 ethesda, MD 20892 USA
Citazione:
N.D. Richert et al., "Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis", MULT SCLER, 7(1), 2001, pp. 49-58

Abstract

Objective: To determine whether lesion evolution in relapsing-remitting multiple sclerosis (RRMS) patients is altered by treatment with interferon beta -1b (IFN beta -1b) or by intravenous methylprednisolone (IVMP) as measured by magnetization transfer imaging Methods: Magnetization transfer ratios(MTR) of 225 contrast enhancing lesions (CEL), in four RRMS patients were serially determined for 12 months before and 12-18 months after contrast enhancement in a baseline vs treatment trial with IFN beta -1b. During the baseline period 185 new CEL were identified: 76 were treated with IVMP (1 g/day x 5 days) and designated steroid CEL (S-CEL); the remaining 109 were considered baseline lesions (B-CEL). During IFN beta -1b treatment, 40 CEL (IFN-CEL) were identified. After image co-registration, regions of interest (ROIs) defining new CEL were transferred to the MTR image set to determine the mean lesion MTR on each monthly exam. The lesion MTR was compared to MTR of normal appearing white matter (NAWM) on the some exam. Results: As earlyos IZ months prior to enhancement the MTR of CEL was reduced compared to NAWM (mean 9.43 +/- 3.2%; P< 0.001). The further reduction in MTR (28% <plus/minus> 4.0) at the time of contrast enhancement was not significantly different for B-CEL S-CEL or IFN-CEL Following enhancement lesion recovery for IFN-CEL (P=0.02) and S-CEL (P=0.002) was significantly higher than B-CEL Conclusion: IFN beta -1b and IVMP reduce tissue damage and promote lesion recovery in RRMS patients. The additional benefit of IVMP compared to IFN beta-1b may be related to its inhibitory effect on demyelination.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 22:06:41